Possible pathogenetic mechanisms of failure epilepsy treatment with carbamazepine
Abstract
This review considers the present model of epileptogenesis, describes the changes of brain structure during ontogeny, as well as a possible mechanism of seizures aggravation during therapy with carbamazepine. Special attention is paid to the GABA-ergic neurotransmission and the advisability of a carbamazepine, depending on age, gender, and physiological factors
About the Authors
K. V. Krikova
НЦПЗ РАМН
Russian Federation
Russian Federation
S. G. Burd
GOU VPO «Russian state medical university named after N.I. Pirogov» of Roszdrav
Russian Federation
Russian Federation
References
1. Болдырева С.Р., Ермаков А.Ю. Сравнительная эффективность карбамазепина, препаратов вальпроевой кислоты и топирамата при височной медиальной эпилепсии у детей. // Журнал Неврологии и психиатрии им. С. С. Корсакова. – 4. – 2010. – 42-47.
2. Aronica E., Boer K., Redeker S., Spliet W. G., van Rijen P. C., Troost D., Gorter J. A. (2007), Neuroscience; 145 (1): 185–96,
3. Babb T. L., Brown W. J. (1987) . In: Engel J. J., editor. Surgical Treatment of the Epilepsies. N. Y.: Raven Press; pp. 511–540.,
4. Babb T. L., Pretorius J. K., Kupfer W. R., Crandall PH. (1989) J. Neurosci.; 9 (7): 2562–74,
5. Beamanoir A., Mira L. (2003) Eds. Beamanoir A., et al. Milan, Italy: John Libby Eurotext: 195-205.
6. Beamanoir A, Mira L. (2003), Eds. Beamanoir A., et al. Milan, Italy: John Libby Eurotext 2003: 195-205
7. Ben-Ari Y., Gaiarsa J. L., Tyzio R., Khazipov R. (2007), Physiol Rev. Oct; 87 (4): 1215-84
8. Bertelli M., Cecchin S., Lapucci C., de Gemmis P., Danieli D., d’Amore E. S., Buttolo L., Giunta F., Mortini P., Pandolfo M. (2007) . Biochim. Biophys. Acta.; 1772 (1): 15–20
9. Blaesse P., Airaksinen M. S., Rivera C., Kaila K. (2009), Neuron. Mar 26; 61 (6): 820-38.
10. Bourgeois B. F. (1998), Brain Dev.; 20 (3): 135–41.
11. Chugani D. C., Muzik O., Juhasz C., Janisse J. J., Ager J., Chugani H. T. (2001) . Ann. Neurol.; 49 (5): 618–26
12. Cobas A., Fairйn A., Alvarez-Bolado G., Sбnchez M. P. (1991), Neuroscience.; 40 (2): 375-97
13. Cohen I., Navarro V., Clemenceau S., Baulac M., Miles R. (2002) Science.; 298 (5597): 1418–21.
14. Crestani F., Assandri R., Tдuber M., Martin J. R., Rudolph U., (2002), Neuropharmacology. Sep; 43 (4): 679-84.
15. Czuczwar S. J., Patsalos P. N. (2001), CNS Drugs. (2001) ; 15 (5): 339–50.,
16. Czuczwar S. J., Patsalos P. N. (2001), CNS Drugs. 2001; 15 (5): 339–50.,
17. Danober L., Deransart C., Depaulis A., Vergnes M., Marescaux C. (1998), Prog Neurobiol. May; 55 (1): 27-57
18. De Simone G., Di Fiore A., Menchise V., Pedone C., Antel J., Casini A., Scozzafava A., Wurl M., Supuran CT. (2005) Bioorg. Med. Chem. Lett.; 15 (9): 2315–20.,
19. Dodgson S. J., Shank R. P., Maryanoff B. E. (2000), Epilepsia.; 41 (Suppl 1): S35–9,
20. Engel J. Jr. (1996), Epilepsy Res. 1996; 26 (1): 141–50,
21. Essrich C., Lorez M., Benson J. A., Fritschy J. M., Lьscher B. (1998) Nat Neurosci. Nov; 1 (7): 563-71
22. Farrant M., Nusser Z. (2005), Nat Rev Neurosci. Mar; 6 (3): 215-29
23. Galanopoulou AS, Kyrozis A, Claudio OI, Stanton PK, Moshй SL. (2003), Exp. Neurol.; 183 (2): 628–637
24. Galanopoulou A.S., Vidaurre J., Moshй S.L. (2002), Dev. Neurosci.; 24 (5): 355–63
25. Galanopoulou A.S., Vidaurre J., Moshй S.L. (2002) . Dev. Neurosci.; 24 (5): 355–63,
26. Galanopoulou AS. (2006) . Eur. J. Neurosci.; 23 (9): 2423–30.
27. Gasser T., Reddington M., Schubert P. (1988), Neurosci Lett., Aug 31; 91 (2): 189-93
28. Ge S., Pradhan D.A., Ming G.L., Song H. (2007), Trends Neurosci. Jan; 30 (1): 1-8.
29. Gobbi G., Tassinari C.A., Roger J, et al. (1989), Neurol Physiol Clin; 19: 209-18.
30. Goffin D., Aarum J., Schroeder J.E., Jovanovic J.N., Chuang T.T. (2008), J. Neurochem. Nov; 107 (4): 964-75
31. Granger P., Biton B., Faure C., Vige X., Depoortere H., Graham D., Langer S.Z., Scatton B., Avenet P. (1995), Mol Pharmacol., Jun; 47 (6): 1189-96
32. Granger P., Biton B., Faure C., Vige X., Depoortere H., Graham D., Langer S.Z., Scatton B., Avenet P. (1995), Mol. Pharmacol. 1995; 47 (6): 1189–96
33. Hauser W.A., Annegers J.F., Kurland L.T. (1935-1984) Epilepsia. 34 (3): 453–68,
34. Hauser W.A. (1990) Neurology.; 40 (5 Suppl 2): 9–13,
35. Hornung J.P., Fritschy J.M. (1996), J. Comp Neurol. Apr 8; 367 (3): 413-30
36. Hosford D.A., Wang Y., Cao Z. (1997), Epilepsy Res. Apr; 27 (1): 55-65.
37. Khalilov I., Holmes G.L., Ben-Ari Y. (2003) Nat. Neurosci; 6 (10): 1079–85.,
38. Khalilov I., Le Van Quyen M., Gozlan H., BenAri Y. (2005) Neuron.; 48 (5): 787–96
39. Kohling R., Lucke A., Straub H., Speckmann E.J., Tuxhorn I., Wolf P., Pannek H., Oppel F. (1998), Brain; 121 (Pt 6): 1073–87,
40. Kostopoulos G., Antoniadis G. (1992) Epilepsy Res.; 8 (Suppl): 125–33
41. Kume A., Greenfield L.J. Jr., Macdonald R.L., Albin R.L. (1996), J. Pharmacol. Exp. Ther.; 277 (3): 1784–92.,
42. Kyrozis A., Chudomel O., Moshй SL., Galanopoulou A.S. (2006). Neurosci. Lett. May 1; 398 (1-2):
43. Laure H., (2007), TURUN YLIOPISTON JULKAISUJA ANNALES UNIVERSITATIS TURKUENSIS SARJA – SER. D OSA – TOM. 781
44. Leinekugel X., Medina I., Khalilov I., Ben-Ari Y., Khazipov R. Neuron. (1997) Feb; 18 (2): 243-55
45. Liu L., Zheng T., Morris M.J., Wallengren C., Clarke A.L., Reid C.A., Petrou S., O’Brien T.J. (2006), J. Pharmacol Exp Ther. Nov; 319 (2): 790-8.
46. LoTurco J.J., Owens D.F., Heath M.J., Davis M.B., Kriegstein A.R. (1995) Neuron. Dec; 15 (6): 1287-98
47. Loup F., Wieser H.G., Yonekawa Y., Aguzzi A., Fritschy J.M. (2000) . J. Neurosci.; 20 (14): 5401–1948. Masereel B., Rolin S., Abbate F., Scozzafava A., Supuran C.T. (2002) J. Med. Chem.; 45 (2): 312–20,
48. Mathern G.W., Pretorius JK, Babb T.L. (1995), J. Neurosurg; 82 (2): 220–7
49. Meldrum B.S., Rogawski MA. (2007), Neurotherapeatics; 4 (1): 18–61
50. Meldrum B.S., Rogawski M.A. (2007), Neurotherapeatics; 4 (1): 18–61.,
51. Mhler H. (2006), Cell Tissue Res. Nov; 326 (2): 505-16.
52. Mosh S.L. Epileptogenesis and the immature brain. (1987) Epilepsia; 28 (Suppl1): S3–15
53. Moshй S.L. Epileptogenesis and the immature brain. Epilepsia. 1987; 28 (Suppl1): S3–15.
54. Munakata M., Watanabe M., Otsuki T., Nakama H., Arima K., Itoh M., Nabekura J., Iinuma K., Tsuchiya S. (2007), Epilepsia.; 48 (4): 837–44
55. Nett S.Т., Jorge-Rivera J.C., Myers M., Clark A.S., Henderson L.P. (1999), J. Neurophysiol; 81 (1): 192–203
56. Nishimori I., Vullo D., Innocenti A., Scozzafava A., Mastrolorenzo A., Supuran C.T. (2005) . Bioorg. Med. Chem. Lett.; 15 (17): 3828–33,
57. Okabe A., Ohno K., Toyoda H., Yokokura M., Sato K., Fukuda A. (2002) Neurosci. Res.; 44 (2): 225–9
58. Okabe A., Yokokura M., Toyoda H., ShimizuOkabe C., Ohno K., Sato K., Fukuda A. (2003), Brain Res. 2003; 990 (1-2): 221–6
59. Okabe A., Yokokura M., Toyoda H., ShimizuOkabe C., Ohno K., Sato K., Fukuda A. (2003). Brain Res.; 990 (1-2): 221–6
60. Olpe H., Kolb C.N., Hausdorf A., Haas H.L. (1991), Experientia, Mar 15; 47 (3): 254-7.
61. Palma E., Amici M., Sobrero F., Spinelli G., Di Angelantonio S., Ragozzino D., Mascia A., Scoppetta C., Esposito V., Miledi R., Eusebi F. (2006), Proc. Natl. Acad. Sci. USA.; 103 (22): 8465–8.)
62. Perucca E., Gram L., Avanzini G., Dulac O., (1998), Epilepsia., Jan; 39 (1): 5-17.
63. Pirker S., Schwarzer C., Wieselthaler A., Sieghart W., Sperk G. (2000), Neuroscience.; 101 (4): 815-50
64. Quilichini P.P., Chiron C., Ben-Ari Y., Gozlan H. (2006), Epilepsia.; 47 (4): 704–16
65. Ravizza T., Friedman L.K., Moshй S.L., Veliskova J. (2003) Int. J. Dev. Neurosci. 2003; 21 (5): 245–54
66. Reiss W.G., Oles K.S. (1996) . Ann. Pharmacother.; 30 (5): 514–9
67. Rivera C., Li H., Thomas-Crusells J., Lahtinen H., Viitanen T., Nanobashvili A., Kokaia Z., Airaksinen M.S., Voipio J., Kaila K., Saarma M. (2002) . J. Cell Biol. 2002; 159 (5): 747–52
68. Rivera C., Voipio J., Kaila K.. (2005), J. Physiol. Jan 1; 562 (Pt 1): 27-36.
69. Rivera C., Voipio J., Payne J.A., Ruusuvuori E., Lahtinen H., Lamsa K., Pirvola U., Saarma M., Kaila K. (1999), Nature. Jan 21; 397 (6716): 251-5.
70. Rudolph U., Crestani F., Benke D., Brьnig I., Benson J.A., Fritschy J.M., Martin J.R., Bluethmann H., Mцhler H. (1999), Nature. Oct 21; 401 (6755): 796-800.
71. Schirrmacher K., Mayer A., Walden J., Dьsing R., Bingmann D. (1995), Eur Neuropsychopharmacol. Dec; 5 (4): 501-7.
72. Tozuka Y., Fukuda S., Namba T., Seki T., Hisatsune T. (2005), Neuron. Sep 15; 47 (6): 803-15.
73. Tuckel K., Jasper H. (1952), Electroencephalogr Clin Neurophysiol; 4: 481-94;
74. Wang D.D., Kriegstein A.R. (2009), J. Physiol. May 1; 587 (Pt 9): 1873-9 76. Willow M., Gonoi T., Catterall W.A., (1985), Mol Pharmacol., May; 27 (5): 549-58.
75. Yuste R., Katz L.C. (1991), Neuron. Mar; 6 (3): 333-44
76. Glauser T., Ben-Menachem E., Bourgeois B., et al. ILAE treatment guidelines: evidencebased analysis of antiepileptic drug efficacy and effectiveness as initia monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-1120.
77. Wheless J.W., Clarke D.F., Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J. Child Neurol 2005; 20 (suppl 1): S1–56.
Review
For citations:
Krikova K.V., Burd S.G. Possible pathogenetic mechanisms of failure epilepsy treatment with carbamazepine. Epilepsy and paroxysmal conditions. 2011;3(1):20-26. (In Russ.)
Views: 476
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
